Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd. and Cipla Ltd. are among drugmakers exploring bids for a portfolio of U.S. generic products Teva Pharmaceutical Industries Ltd. is selling, according to people with knowledge of the matter.
Novartis AG’s generics unit Sandoz is also among about 30 companies weighing offers for the portfolio, the people said, asking not to be identified as the matter is private. Second-round bids are due this week and the sale could fetch from $500 million to $800 million, one of the people said.
